Note! Please note that this article is currently in the "Article in Press" stage and is not the final "Version of record". While it has been accepted, copy-edited, and formatted, however, it is still undergoing proofreading and corrections by the authors. Therefore, the text may still change before the final publication. Although "Articles in Press" may not have all bibliographic details available, the DOI and the year of online publication can still be used to cite them. The article title, DOI, publication year, and author(s) should all be included in the citation format. Once the final "Version of record" becomes available the "Article in Press" will be replaced by that.
Abstract
Background: Trastuzumab deruxtecan (T-DXd) has shown promising outcomes as a second or subsequent-line treatment for human epidermal growth factor-2 (HER2)-positive advanced gastric or gastroesophageal junction cancer.
Case Presentation: We reported a 49-year-old male patient with stage IV HER2-amplified gastric cancer. Despite extensive pretreatments, including first-line trastuzumab plus FOLFOX, second-- line trastuzumab plus FOLFOX, followed by traditional Chinese medicine, third-line nivolumab plus trastuzumab, fourth-line pyrotinib plus paclitaxel and five hepatic arterial chemoembolization procedures, and fifth-line pembrolizumab plus nab-paclitaxel and thoracic radiotherapy, the patient experienced disease progression. In April 2021, T-DXd was initiated as the sixth-line therapy in combination with radiotherapy for brain metastases. After one treatment cycle, the patient achieved a partial response. T-DXd was discontinued in August 2022 due to recurrent anemia attributed to cardiac stenosis-related bleeding.
Conclusion: The condition of the patient remained stable until May 2023, indicating a progression-free survival of over 24 months. This case suggests that T-DXd may offer long-term clinical benefits in patients with HER2-amplified advanced gastric cancer with brain metastases.
[1]
Thrift, A.P.; Wenker, T.N.; El-Serag, H.B. Global burden of gastric cancer: Epidemiological trends, risk factors, screening and prevention. Nat. Rev. Clin. Oncol., 2023, 20(5), 338-349.
[http://dx.doi.org/10.1038/s41571-023-00747-0] [PMID: 36959359]
[http://dx.doi.org/10.1038/s41571-023-00747-0] [PMID: 36959359]
[3]
Lordick, F.; Carneiro, F.; Cascinu, S.; Fleitas, T.; Haustermans, K.; Piessen, G.; Vogel, A.; Smyth, E.C. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol., 2022, 33(10), 1005-1020.
[http://dx.doi.org/10.1016/j.annonc.2022.07.004] [PMID: 35914639]
[http://dx.doi.org/10.1016/j.annonc.2022.07.004] [PMID: 35914639]
[4]
A. Japanese Gastric Cancer Treatment Guidelines 2021. In: Gastric Cancer, 6th edition; , 2023; 26, pp. (1)1-25.
[6]
Hayes, D.F.; Picard, M.H. Heart of darkness: The downside of trastuzumab. J. Clin. Oncol., 2006, 24(25), 4056-4058.
[http://dx.doi.org/10.1200/JCO.2006.07.5143] [PMID: 16908930]
[http://dx.doi.org/10.1200/JCO.2006.07.5143] [PMID: 16908930]
[7]
Marei, H.E.; Cenciarelli, C.; Hasan, A. Potential of antibody–drug conjugates (ADCs) for cancer therapy. Cancer Cell Int., 2022, 22(1), 255.
[http://dx.doi.org/10.1186/s12935-022-02679-8] [PMID: 35964048]
[http://dx.doi.org/10.1186/s12935-022-02679-8] [PMID: 35964048]
[8]
Fu, Z.; Li, S.; Han, S.; Shi, C.; Zhang, Y. Antibody drug conjugate: The “biological missile” for targeted cancer therapy. Signal Transduct. Target. Ther., 2022, 7(1), 93.
[http://dx.doi.org/10.1038/s41392-022-00947-7] [PMID: 35318309]
[http://dx.doi.org/10.1038/s41392-022-00947-7] [PMID: 35318309]
[9]
Chau, C.H.; Steeg, P.S.; Figg, W.D. Antibody–drug conjugates for cancer. Lancet, 2019, 394(10200), 793-804.
[http://dx.doi.org/10.1016/S0140-6736(19)31774-X] [PMID: 31478503]
[http://dx.doi.org/10.1016/S0140-6736(19)31774-X] [PMID: 31478503]
[10]
Ogitani, Y.; Aida, T.; Hagihara, K.; Yamaguchi, J.; Ishii, C.; Harada, N.; Soma, M.; Okamoto, H.; Oitate, M.; Arakawa, S.; Hirai, T.; Atsumi, R.; Nakada, T.; Hayakawa, I.; Abe, Y.; Agatsuma, T. DS-8201a, A novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. Clin. Cancer Res., 2016, 22(20), 5097-5108.
[http://dx.doi.org/10.1158/1078-0432.CCR-15-2822] [PMID: 27026201]
[http://dx.doi.org/10.1158/1078-0432.CCR-15-2822] [PMID: 27026201]
[11]
Ogitani, Y.; Hagihara, K.; Oitate, M.; Naito, H.; Agatsuma, T. Bystander killing effect of DS -8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci., 2016, 107(7), 1039-1046.
[http://dx.doi.org/10.1111/cas.12966] [PMID: 27166974]
[http://dx.doi.org/10.1111/cas.12966] [PMID: 27166974]
[12]
Shitara, K.; Iwata, H.; Takahashi, S.; Tamura, K.; Park, H.; Modi, S.; Tsurutani, J.; Kadowaki, S.; Yamaguchi, K.; Iwasa, S.; Saito, K.; Fujisaki, Y.; Sugihara, M.; Shahidi, J.; Doi, T. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: A dose-expansion, phase 1 study. Lancet Oncol., 2019, 20(6), 827-836.
[http://dx.doi.org/10.1016/S1470-2045(19)30088-9] [PMID: 31047804]
[http://dx.doi.org/10.1016/S1470-2045(19)30088-9] [PMID: 31047804]
[13]
Shitara, K.; Bang, Y.J.; Iwasa, S.; Sugimoto, N.; Ryu, M.H.; Sakai, D.; Chung, H.C.; Kawakami, H.; Yabusaki, H.; Lee, J.; Saito, K.; Kawaguchi, Y.; Kamio, T.; Kojima, A.; Sugihara, M.; Yamaguchi, K. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N. Engl. J. Med., 2020, 382(25), 2419-2430.
[http://dx.doi.org/10.1056/NEJMoa2004413] [PMID: 32469182]
[http://dx.doi.org/10.1056/NEJMoa2004413] [PMID: 32469182]
[14]
Yoshida, J.; Sugiyama, K.; Satoh, M.; Shiraishi, K.; Nishibori, R.; Kitagawa, C. Efficacy of trastuzumab deruxtecan in an advanced gastric cancer patient with brain metastasis. Curr. Probl. Cancer, 2021, 45(6), 100757.
[http://dx.doi.org/10.1016/j.currproblcancer.2021.100757] [PMID: 33892964]
[http://dx.doi.org/10.1016/j.currproblcancer.2021.100757] [PMID: 33892964]
[15]
Ogata, T.; Fujita, Y.; Muro, K. Dramatic response to trastuzumab deruxtecan rechallenge in a patient with HER2-positive gastric cancer: A case report. Am. J. Case Rep., 2022, 23, e935600.
[http://dx.doi.org/10.12659/AJCR.935600] [PMID: 35241641]
[http://dx.doi.org/10.12659/AJCR.935600] [PMID: 35241641]
[16]
King, D.A.; Weiel, J.J.; Reyes, R.; Mills, M.; Itchon, A.; Fisher, G.A.; Ford, J.M.; Suarez, C.J. Therapeutic implications of oncogenic missense HER2 ( ERBB2 ) mutations in gastric adenocarcinoma. JCO Precis. Oncol., 2023, 7(7), e2200093.
[http://dx.doi.org/10.1200/PO.22.00093] [PMID: 36787506]
[http://dx.doi.org/10.1200/PO.22.00093] [PMID: 36787506]
[17]
Terashima, T.; Yamashita, T.; Takabatake, H.; Nakanuma, S.; Kinoshita, J.; Yagi, S.; Mizukoshi, E.; Harada, K.; Fushida, S.; Kaneko, S. Successful second conversion surgery after trastuzumab deruxtecan for recurrent HER2-positive gastric cancer. Clin. J. Gastroenterol., 2023, 16(3), 330-335.
[http://dx.doi.org/10.1007/s12328-023-01764-3] [PMID: 36708503]
[http://dx.doi.org/10.1007/s12328-023-01764-3] [PMID: 36708503]
[18]
Amagai, H.; Sasagawa, S.; Koide, Y.; Tsukamoto, S.; Miyazawa, Y.; Yamakawa, H.; Murayama, H.; Sentsui, T.; Matsubara, H.; Yamazaki, K.; Yarita, T. A patient with afp-producing gastric cancer and stenosis who regained oral intake capabilities after T-DXd treatment]. Cancer Sci., 2023, 50(7), 813-816.
[PMID: 37496227]
[PMID: 37496227]
[19]
Taniguchi, H.; Yagisawa, M.; Satoh, T.; Kadowaki, S.; Sunakawa, Y.; Nishina, T.; Komatsu, Y.; Esaki, T.; Sakai, D.; Doi, A.; Kajiwara, T.; Ono, H.; Asano, M.; Hirano, N.; Odegaard, J.I.; Fujii, S.; Nomura, S.; Sato, A.; Yoshino, T.; Nakamura, Y. Tissue-agnostic efficacy of trastuzumab deruxtecan (T-DXd) in advanced solid tumors with HER2 amplification identified by plasma cell-free DNA (cfDNA) testing: Results from a phase 2 basket trial (HERALD/EPOC1806). J. Clin. Oncol., 2023, 41(16_suppl)(Suppl.), 3014-3014.
[http://dx.doi.org/10.1200/JCO.2023.41.16_suppl.3014]
[http://dx.doi.org/10.1200/JCO.2023.41.16_suppl.3014]
[20]
Shitara, K.; Bang, Y.; Iwasa, S.; Sugimoto, N.; Ryu, M.; Sakai, D.; Chung, H.; Omuro, Y.; Kawakami, H.; Yabusaki, H.; Sakamoto, Y.; Nishina, T.; Inaki, K.; Kuwahara, Y.; Suto, F.; Sugihara, M.; Saito, K.; Kojima, A.; Yamaguchi, K. O-14 Exploratory biomarker analysis of trastuzumab deruxtecan in DESTINY-Gastric01, a randomized, phase 2, multicenter, open-label study in patients with HER2-positive or -low advanced gastric or gastroesophageal junction adenocarcinoma. Ann. Oncol., 2021, 32, S224.
[http://dx.doi.org/10.1016/j.annonc.2021.05.018]
[http://dx.doi.org/10.1016/j.annonc.2021.05.018]
[21]
Zhang, L.; Hamdani, O.; Gjoerup, O.; Cho-Phan, C.; Snider, J.; Castellanos, E.; Nimeiri, H.; Frampton, G.; Venstrom, J.M.; Oxnard, G.; Klempner, S.J.; Schrock, A.B. ERBB2 copy number as a quantitative biomarker for real-world outcomes to anti–human epidermal growth factor receptor 2 therapy in advanced gastroesophageal adenocarcinoma. JCO Precis. Oncol., 2022, 6(6), e2100330.
[http://dx.doi.org/10.1200/PO.21.00330] [PMID: 35050711]
[http://dx.doi.org/10.1200/PO.21.00330] [PMID: 35050711]
[22]
Gao, J.; Wang, H.; Zang, W.; Li, B.; Rao, G.; Li, L.; Yu, Y.; Li, Z.; Dong, B.; Lu, Z.; Jiang, Z.; Shen, L. Circulating tumor DNA functions as an alternative for tissue to overcome tumor heterogeneity in advanced gastric cancer. Cancer Sci., 2017, 108(9), 1881-1887.
[http://dx.doi.org/10.1111/cas.13314] [PMID: 28677165]
[http://dx.doi.org/10.1111/cas.13314] [PMID: 28677165]
[23]
Zhang, C.; Chen, Z.; Chong, X.; Chen, Y.; Wang, Z.; Yu, R.; Sun, T.; Chen, X.; Shao, Y.; Zhang, X.; Gao, J.; Shen, L. Clinical implications of plasma ctDNA features and dynamics in gastric cancer treated with HER2‐targeted therapies. Clin. Transl. Med., 2020, 10(8), e254.
[http://dx.doi.org/10.1002/ctm2.254] [PMID: 33377634]
[http://dx.doi.org/10.1002/ctm2.254] [PMID: 33377634]
[24]
Wang, H.; Li, B.; Liu, Z.; Gong, J.; Shao, L.; Ren, J.; Niu, Y.; Bo, S.; Li, Z.; Lai, Y.; Lu, S.; Gao, J.; Shen, L. HER2 copy number of circulating tumour DNA functions as a biomarker to predict and monitor trastuzumab efficacy in advanced gastric cancer. Eur. J. Cancer, 2018, 88, 92-100.
[http://dx.doi.org/10.1016/j.ejca.2017.10.032] [PMID: 29207318]
[http://dx.doi.org/10.1016/j.ejca.2017.10.032] [PMID: 29207318]
[25]
Hino, K.; Nishina, T.; Kajiwara, T.; Bando, H.; Nakamura, M.; Kadowaki, S.; Minashi, K.; Yuki, S.; Ohta, T.; Hara, H.; Mizukami, T.; Moriwaki, T.; Ohtsubo, K.; Komoda, M.; Mitani, S.; Nagashima, F.; Kato, K.; Yamada, T.; Hasegawa, H.; Yamazaki, K.; Yoshino, T.; Hyodo, I. Association of ERBB2 copy number and gene coalterations with trastuzumab efficacy and resistance in human epidermal growth factor receptor 2–positive esophagogastric and gastric cancer. JCO Precis. Oncol., 2022, 6(6), e2200135.
[http://dx.doi.org/10.1200/PO.22.00135] [PMID: 35952320]
[http://dx.doi.org/10.1200/PO.22.00135] [PMID: 35952320]
[26]
Han, S.; Lim, K.S.; Blackburn, B.J.; Yun, J.; Putnam, C.W.; Bull, D.A.; Won, Y.W. The potential of topoisomerase inhibitor-based antibody–drug conjugates. Pharmaceutics, 2022, 14(8), 1707.
[http://dx.doi.org/10.3390/pharmaceutics14081707] [PMID: 36015333]
[http://dx.doi.org/10.3390/pharmaceutics14081707] [PMID: 36015333]
[27]
Sasaki, A.; Kawazoe, A.; Eto, T.; Okunaka, M.; Mishima, S.; Sawada, K. Improved efficacy of taxanes and ramucirumab combination chemotherapy after exposure to anti-PD-1 therapy in advanced gastric cancer. ESMO Open., 2020, 4(Suppl 2)
[http://dx.doi.org/10.1136/esmoopen-2020-000775]
[http://dx.doi.org/10.1136/esmoopen-2020-000775]
[28]
Kankeu Fonkoua, L.A.; Chakrabarti, S.; Sonbol, M.B.; Kasi, P.M.; Starr, J.S.; Liu, A.J.; Nevala, W.K.; Maus, R.L.; Bois, M.C.; Pitot, H.C.; Chandrasekharan, C.; Ross, H.J.; Wu, T.T.; Graham, R.P.; Villasboas, J.C.; Weiss, M.; Foster, N.R.; Markovic, S.N.; Dong, H.; Yoon, H.H. Outcomes on ANTI-VEGFR -2/paclitaxel treatment after progression on immune checkpoint inhibition in patients with metastatic gastroesophageal adenocarcinoma. Int. J. Cancer, 2021, 149(2), 378-386.
[http://dx.doi.org/10.1002/ijc.33559] [PMID: 33739449]
[http://dx.doi.org/10.1002/ijc.33559] [PMID: 33739449]
[29]
Tincknell, G.; Naveed, A.; Nankervis, J.; Mukhtiar, A.; Piper, A.K.; Becker, T.M.; Chantrill, L.; Aghmesheh, M.; Vine, K.L.; Ranson, M.; Brungs, D. HER2-positive gastroesophageal cancers are associated with a higher risk of brain metastasis. Cancers, 2022, 14(23), 5754.
[http://dx.doi.org/10.3390/cancers14235754] [PMID: 36497236]
[http://dx.doi.org/10.3390/cancers14235754] [PMID: 36497236]
[30]
Stemmler, H.J.; Schmitt, M.; Willems, A.; Bernhard, H.; Harbeck, N.; Heinemann, V. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood–brain barrier. Anticancer Drugs, 2007, 18(1), 23-28.
[http://dx.doi.org/10.1097/01.cad.0000236313.50833.ee] [PMID: 17159499]
[http://dx.doi.org/10.1097/01.cad.0000236313.50833.ee] [PMID: 17159499]
Related Journals
Anti-Cancer Agents in Medicinal Chemistry
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Current Bioactive Compounds
Combinatorial Chemistry & High Throughput Screening
Current Cancer Therapy Reviews
Current Diabetes Reviews
Current Drug Safety
Current Drug Targets
Current Drug Therapy
Current Drug Metabolism
Related Books
Anthocyanins: Pharmacology and Nutraceutical Importance
The Roles and Responsibilities of Clinical Pharmacists in Hospital Settings
Bioactive Compounds from Medicinal Plants for Cancer Therapy and Chemoprevention
Drug Addiction Mechanisms in the Brain
Software and Programming Tools in Pharmaceutical Research
Objective Pharmaceutics: A Comprehensive Compilation of Questions and Answers for Pharmaceutics Exam Prep
Medicinal Chemistry of Drugs Affecting Cardiovascular and Endocrine Systems
Frontiers in Clinical Drug Research - Anti-Cancer Agents
The Management of Metastatic Triple-Negative Breast Cancer: An Integrated and Expeditionary Approach
Advanced Pharmacy
